Economic Evaluation of the Use of Nadroparin Calcium in the Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Surgical Patients in Italy
- 25 Downloads
The objective of this study was to compare the costs, from the perspective of the payer, of using nadroparin calcium, a low-molecular-weight heparin, instead of unfractionated heparin in the prophylaxis of venous thromboembolism in patients undergoing orthopaedic surgery or major general surgery in Italy.
The methods used were based on a published meta-analysis and a survey of clinical practice. We constructed a model of the prophylaxis and management of venous thromboembolism in Italy. Resource use associated with individual events was estimated on the basis of the clinical survey. Unit costs, not available from published sources, were taken from charges made by hospitals and from direct observation. A sensitivity analysis was conducted to examine whether the results were robust to changes in key variables.
In the base case, compared with unfractionated heparin, prophylaxis with nadroparin calcium reduced the expected costs of managing thromboembolism by 267 226 Italian lire (L, 1994 values; $US 1 = L1600 approx.) per patient undergoing orthopaedic surgery, and by L45 588 per patient undergoing major general surgery. Therefore, switching from unfractionated heparin to nadroparin calcium in these patients offers the possibility of significant cost savings to the Italian healthcare system.
KeywordsPulmonary Embolism Adis International Limited Deep Vein Thrombosis Venous Thromboembolism Unfractionated Heparin
Unable to display preview. Download preview PDF.
- 2.Prevention of venous thromboembolism: European consensus statement. Developed under the auspices of the Cardiovascular Disease Education and Research Trust; 1991 Nov 1-5; Windsor. Cyprus: Med-Orion Publishing Company, 1992Google Scholar
- 3.Wille-Jørgesen P. Prophylaxis of postoperative thromboembolism. Dan Med Bull 1991; 38: 203–28Google Scholar
- 6.Drug Information Pharmacists, South West Thames, New Product Assessment. Low-molecular-weight heparins. London: Drug Information Pharmacists Group, 1991Google Scholar
- 8.Frydman AM, Bara L, Le Roux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 ml. J Clin Pharmacol 1988; 8: 609–18Google Scholar
- 10.Deehavanne M, Ville D, Berruyer M, et al. Randomized trial of a low molecular weight heparin (Kabi 2165) versus adjusted dose subcutaneous standard heparin in the prophylaxis of deep vein thrombosis after elective hip surgery. Haemostasis 1989; 1: 5–12Google Scholar
- 12.Eriksson BI, Eriksson E, Wudenvik H, et al. Comparison of low molecular weight heparin and unfractionated heparin in prophylaxis of deep vein thrombosis and pulmonary embolism in total hip replacement [abstract]. Thromb Haemostas 1989; 62: 470Google Scholar
- 16.Leyvraz PF, Postel M, Bachmann F, et al. Prevention of deep vein thrombosis after total hip replacement: randomized comparison between adjusted dose unfractionated heparin and low molecular weight heparin (CY216). In: Hoeck lA, editor. Deep vein thrombosis following total hip replacement. Amsterdam: University of Amsterdam, 1990Google Scholar
- 17.Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemostas 1988; 60: 407–11Google Scholar
- 28.Law Om n 80, 7 XI 1991, Gazzetta Ufficiale n 2876, Rome: Italian Government, 1991 Dec 6Google Scholar
- 30.Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med; 34 (11): 682–7Google Scholar